NR1H2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL35281	0.78	20/20
SCHEMBL35302	0.77	20/20
SCHEMBL34991	0.76	20/20
SCHEMBL35403	0.75	20/20
SCHEMBL34978	0.74	20/20
SCHEMBL35473	0.74	20/20
SCHEMBL35422	0.72	20/20
SCHEMBL34830	0.70	20/20
SCHEMBL38954	0.70	20/20
SCHEMBL102900	0.69	20/20
SCHEMBL103788	0.68	20/20
SCHEMBL105121	0.68	20/20
SCHEMBL35113	0.68	20/20
SCHEMBL35265	0.67	20/20
SCHEMBL35292	0.67	20/20
SCHEMBL35409	0.66	20/20
SCHEMBL34599	0.65	20/20
SCHEMBL35571	0.65	20/20
SCHEMBL105506	0.65	20/20
SCHEMBL106165	0.64	20/20

Clinical trials — most relevant to NR1H2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Silymarin in Rheumatoid Arthritis Patients Treated With Methotrexate	PHASE4	NOT_YET_RECRUITING
Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes	PHASE4	COMPLETED
LDL Receptor Under Ezetimibe and Simvastatin	PHASE4	COMPLETED
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons	PHASE4	COMPLETED
Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis	PHASE3	COMPLETED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)	PHASE3	UNKNOWN
Fibrates in Pediatric Cholestasis	PHASE2	COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis	PHASE2	UNKNOWN
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis	PHASE2	ACTIVE_NOT_RECRUITING
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment	PHASE2	UNKNOWN
Cholic Acid for Hepatic Steatosis in Lipodystrophy	PHASE2	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Study of Gemcabene in Adults With FPLD	PHASE1/PHASE2	COMPLETED
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer	PHASE1	COMPLETED
Choline Effects - Pre-symptomatic AD	PHASE1	COMPLETED
LXR and Oocyte Meiosis Resumption	nan	UNKNOWN
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)	nan	RECRUITING
Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT	nan	COMPLETED
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy	nan	NOT_YET_RECRUITING
Mechanisms of Glucose Lowering Effect of Colesevelam HCl	nan	COMPLETED
Epidemiology of Atherosclerosis	nan	COMPLETED
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health	nan	UNKNOWN
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes	nan	COMPLETED
FGF19 in Obstructive Cholestasis: Unveil the Signal	nan	UNKNOWN
A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome	nan	COMPLETED
Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism	nan	UNKNOWN
Prospective Assessment of Atherosclerotic Cardiovascular Disease (ASCVD) Risk	nan	UNKNOWN
Statin Therapy and COVID-19 Infection	nan	COMPLETED
Ekvasis of Atorvastatin (Antorcin®) Treatment in Patients With Acute Cardiovascular Events	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NR1H2 binder may also engage these)

Protein	Name	Similarity
Q62755	—	1.000	Q62755 →
Q5E9B6	—	1.000	Q5E9B6 →
F1QLY4	—	0.999	F1QLY4 →
Q60644	—	0.998	Q60644 →
P51448	—	0.998	P51448 →
Q5BIS6	—	0.997	Q5BIS6 →
Q28037	—	0.997	Q28037 →
P79387	—	0.997	P79387 →
P28704	—	0.997	P28704 →
Q5TJF7	—	0.996	Q5TJF7 →
VDR	Vitamin D3 receptor	0.996	landscape →
Q5QJV7	—	0.996	Q5QJV7 →
NR1H3	Oxysterols receptor LXR-alpha	0.996	landscape →
Q6QMY5	—	0.995	Q6QMY5 →
Q62685	—	0.995	Q62685 →
RORA	Nuclear receptor ROR-alpha	0.994	landscape →
Q05343	—	0.994	Q05343 →
Q90416	—	0.994	Q90416 →
P10589	—	0.994	P10589 →
ESRRB	Steroid hormone receptor ERR2	0.994	landscape →
Q95L87	—	0.993	Q95L87 →
P50569	—	0.993	P50569 →
Q60632	—	0.993	Q60632 →
P33242	—	0.993	P33242 →
P43135	—	0.993	P43135 →
NR4A1	Nuclear receptor subfamily 4immunitygroup A member 1	0.993	landscape →
Q9W785	—	0.993	Q9W785 →
O09018	—	0.993	O09018 →
Q9YGL3	—	0.993	Q9YGL3 →
Q9GKL2	—	0.992	Q9GKL2 →